Greenleaf Trust Sells 2,047 Shares of Eli Lilly and Company $LLY

Key Points

• Greenleaf Trust sold 2,047 shares of Eli Lilly and Company, reducing its holdings by 7.8%, leaving it with 24,090 shares valued at $18,779,000.
• During the latest quarter, Eli Lilly reported revenue of $15.56 billion and an EPS of $6.31, exceeding analyst estimates, with revenue growth of 37.6% compared to the previous year.
• Institutional investors collectively own 82.53% of Eli Lilly's stock, with various hedge funds adjusting their positions significantly in the past quarter.

Greenleaf Trust decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,090 shares of the company's stock after selling 2,047 shares during the quarter. Greenleaf Trust's holdings in Eli Lilly and Company were worth $18,779,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of LLY. WestEnd Advisors LLC raised its holdings in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $27,000. Citizens National Bank Trust Department raised its stake in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. bought a new position in shares of Eli Lilly and Company in the 1st quarter valued at approximately $40,000. Finally, TD Capital Management LLC lifted its holdings in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after purchasing an additional 31 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.1%

Shares of Eli Lilly and Company stock opened at $725.54 on Tuesday. The company has a market capitalization of $686.69 billion, a P/E ratio of 47.42, a price-to-earnings-growth ratio of 1.01 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The business has a 50-day moving average of $733.42 and a two-hundred day moving average of $765.98. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the firm posted $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on LLY shares. UBS Group lowered their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Leerink Partnrs downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Thursday, August 7th. JPMorgan Chase & Co. dropped their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday, September 16th. Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, HSBC raised Eli Lilly and Company from a "reduce" rating to a "hold" rating and raised their price target for the company from $675.00 to $700.00 in a research report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $939.61.

Insider Transactions at Eli Lilly and Company

In related news, CEO David A. Ricks acquired 1,632 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.